Rationale for the EUCAST clinical breakpoints

First Page		Document Content
Date: 2011-05-04 15:48:53 Antifungals Yeasts Fungal diseases Echinocandins Pfizer Candida krusei Fungemia Candidiasis Anidulafungin Biology Mycology Microbiology		Rationale for the EUCAST clinical breakpoints Add to Reading List Source URL: www.eucast.org Download Document from Source Website File Size: 170,61 KB Share Document on Facebook

	Rationale for the EUCAST clinical breakpoints DocID: 1aHRT - View Document
	Costs Associated with Candidemia in a Hospital Setting Joshua J. Gagne, PharmD, Ross E. Breitbart, MS, Vittorio Maio, PharmD, MS, MSPH, David L. Horn, MD, Christine W. Hartmann, MSS, PhD, Robert Swanson, PhD, and Neil I. DocID: 1ab11 - View Document
	IOSR Journal Of Pharmacy (e)-ISSN: , (p)-ISSN: www.iosrphr.org Volume 5, Issue 4 (April 2015), PPCandiduria: current scenario 1 DocID: 1853s - View Document
	Determination of Optimal PNA FISH Testing Times in a Major Medical Center F. J. Brewster, K. C. Hazen, S. I. Getchell-White Univ. of Virginia Health System, Charlottesville, VA Abstract DocID: 15KTl - View Document
	PowerPoint Presentation - Slide 1 DocID: 12Vqd - View Document